A Phase I study to evaluate the Pharmacokinetics and Safety of Letrozole LEBE in Healthy Post-menopausal Women.

2023-503948-13-00 Human pharmacology (Phase I) - Other Ended

Start 20 Jul 2023 · End 11 Mar 2026 · Status Ended · 2 EU/EEA countries · 4 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 105
Countries 2
Sites 4

Healthy Post-menopausal women.

Key facts

Sponsor
Laboratorios Farmaceuticos Rovi S.A.
Participant type
Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
20 Jul 2023 → 11 Mar 2026
Decision date (initial)
2025-02-13
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Healthy Post-menopausal women.

VersionLevelCodeTermSystem organ class
21.1 PT 10051775 Postmenopause 100000004869

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Laboratorios Farmaceuticos Rovi S.A.

Sponsor organisation
Laboratorios Farmaceuticos Rovi S.A.
Address
Calle De Julian Camarillo 35, Poligono Julian Camarillo Norte Poligono Julian Camarillo Norte
City
Madrid
Postcode
28037
Country
Spain

Scientific contact point

Organisation
Laboratorios Farmaceuticos Rovi S.A.
Contact name
Rovi Medical Department

Public contact point

Organisation
Laboratorios Farmaceuticos Rovi S.A.
Contact name
Rovi Medical Department

Locations

2 EU/EEA countries · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
Bulgaria Ended 15 2
Czechia Ended 90 2
Rest of world 0

Investigational sites

Bulgaria

2 sites · Ended
Medical Center Comac Medical Ltd.
N/A, Ulitsa Urvich 13, Krasno Selo District, Sofia
Medical Center Comac Medical Ltd.
N/A, Ulitsa Sveti Georgi Sofiyski 3, 1606, Sofia

Czechia

2 sites · Ended
Quinta-Analytica s.r.o.
N/A, Umelecka 305/1, Moravska Ostrava, Moravska Ostrava A Privoz
Quinta-Analytica s.r.o.
Klinika onkologie a radioterapie, Prazska 1486/18c, Hostivar, Prague 15

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Czechia 2023-07-20 2026-03-11 2023-07-20 2025-06-06

Application history

10 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-03-22 Czechia Acceptable
2023-07-11
2023-07-12
2 NON SUBSTANTIAL MODIFICATION NSM-1 2023-08-29 Czechia Acceptable
2023-07-11
2023-08-29
3 SUBSTANTIAL MODIFICATION SM-1 2023-10-05 Czechia Acceptable
2023-11-15
2023-11-16
4 NON SUBSTANTIAL MODIFICATION NSM-2 2024-01-15 Czechia Acceptable
2023-11-15
2024-01-15
5 SUBSTANTIAL MODIFICATION SM-3 2024-01-29 Czechia Acceptable
2024-02-26
2024-04-16
6 NON SUBSTANTIAL MODIFICATION NSM-3 2024-07-05 Czechia Acceptable
2024-02-26
2024-07-05
7 SUBSEQUENT ADDITION OF MSC APP-7 2024-11-20 Acceptable
2024-02-26
2025-02-13
8 NON SUBSTANTIAL MODIFICATION NSM-4 2025-05-13 Czechia Acceptable
2024-02-26
2025-05-13
9 NON SUBSTANTIAL MODIFICATION NSM-5 2025-09-04 Czechia Acceptable
2024-02-26
2025-09-04
10 NON SUBSTANTIAL MODIFICATION NSM-6 2026-03-24 Czechia Acceptable
2024-02-26
2026-03-24